Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $8.16 billion. The enterprise value is $6.54 billion.
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 144.40 million shares outstanding. The number of shares has increased by 7.07% in one year.
| Current Share Class | 144.40M |
| Shares Outstanding | 144.40M |
| Shares Change (YoY) | +7.07% |
| Shares Change (QoQ) | +2.25% |
| Owned by Insiders (%) | 0.60% |
| Owned by Institutions (%) | 106.18% |
| Float | 132.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.72 |
| P/TBV Ratio | 2.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.04.
| Current Ratio | 7.49 |
| Quick Ratio | 7.18 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.55% and return on invested capital (ROIC) is -21.27%.
| Return on Equity (ROE) | -30.55% |
| Return on Assets (ROA) | -20.23% |
| Return on Invested Capital (ROIC) | -21.27% |
| Return on Capital Employed (ROCE) | -35.05% |
| Weighted Average Cost of Capital (WACC) | 10.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.87M |
| Employee Count | 507 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.81% in the last 52 weeks. The beta is 1.24, so Vaxcyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | +70.81% |
| 50-Day Moving Average | 52.93 |
| 200-Day Moving Average | 49.58 |
| Relative Strength Index (RSI) | 67.46 |
| Average Volume (20 Days) | 1,848,782 |
Short Selling Information
The latest short interest is 14.47 million, so 10.02% of the outstanding shares have been sold short.
| Short Interest | 14.47M |
| Short Previous Month | 13.79M |
| Short % of Shares Out | 10.02% |
| Short % of Float | 10.96% |
| Short Ratio (days to cover) | 8.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.09B |
| Pretax Income | -946.53M |
| Net Income | -946.53M |
| EBITDA | -1.07B |
| EBIT | -1.09B |
| Earnings Per Share (EPS) | -$6.91 |
Full Income StatementBalance Sheet
The company has $1.74 billion in cash and $116.30 million in debt, giving a net cash position of $1.62 billion or $11.23 per share.
| Cash & Cash Equivalents | 1.74B |
| Total Debt | 116.30M |
| Net Cash | 1.62B |
| Net Cash Per Share | $11.23 |
| Equity (Book Value) | 3.00B |
| Book Value Per Share | 20.76 |
| Working Capital | 1.57B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$769.93 million and capital expenditures -$45.02 million, giving a free cash flow of -$814.94 million.
| Operating Cash Flow | -769.93M |
| Capital Expenditures | -45.02M |
| Depreciation & Amortization | 16.39M |
| Net Borrowing | n/a |
| Free Cash Flow | -814.94M |
| FCF Per Share | -$5.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |